Thursday September 10, 2015 0 comments
ENGLEWOOD -- Aytu BioScience Inc. (OTCQB: AYTU), a specialty health care company developing treatments for urological and related conditions, announced the appointment of Jonathan Heath McGrael as VP of sales.
McGrael has significant experience building health care sales organizations and will be responsible for launching and establishing Aytu’s commercial infrastructure for its FDA-approved Prostascint and other late-stage products, the company said.
“We’re looking forward to working again with Jon based on his tremendous success with our prior company, Arbor Pharmaceuticals,” said Josh Disbrow, Aytu CEO.
“We are exceedingly confident in his ability to lead our commercial efforts at Aytu. As we commence with market development initiatives and look to build on our initial sales for Aytu, Jon’s expertise and broad commercial experience will be invaluable.”
McGrael has spent 17 years in the pharmaceutical industry and has held positions of increasing responsibility in sales, sales training, marketing, sales management and leadership development. He was most recently director of sales at Arbor Pharmaceuticals, leading a sales organization that grew from 10 to more than 400.
“I am thrilled to join the management team at Aytu,” said McGrael. “ It feels good to be back together with the core group that brought success to our previous endeavor, and to have a strong path forward with on-market assets that will make possible the early commercial build we need to bring our pipeline products to patients.”